bioRxivNeurosciencePreprint
Epigenomic anomalies in induced pluripotent stem cells from Alzheimer disease cases
Anthony FlamieriD, Alisar KatbeiD, Dounya Serhani, Rimi Hamam, Ryan HoganiD, Erika Sendra TavaresiD, Elise HéoniD, Roy HannaiD, Gilbert BernieriD
- Citations
- 0
Abstract
Reprogramming of adult somatic cells into induced pluripotent stem cells (iPSCs) resets the aging clock. However, primed iPSCs can retain cell-of-origin epigenomic marks, especially those linked to heterochromatin and lamina-associated regions. Here we show that iPSCs produced from dermal fibroblasts of late-onset sporadic Alzheimers disease (AD) cases retain epigenomic anomalies that supersede developmental defects and neurodegeneration. When compared to iPSCs from elderly controls, AD iPSCs show reduced BMI1 expression, lower H3K9me3 levels, and an altered DNA methylome. Gene Ontology analysis of differentially methylated DNA regions (DMRs) reveals terms linked to cell-cell adhesion and synapse, with the cognitive resilience-associated MEF2 family of transcription factors being the most enriched at DMRs. Upon noggin exposure, AD iPSCs show lesser efficient neural induction and forebrain specification, together with increased ZIC2, ZIC5 and WNT-related gene expression. Long-term AD neuronal cultures present a dedifferentiation and loss-of-cell identity phenotype. Despite these epigenomic anomalies, AD iPSCs generate cortical neurons in normal proportion and readily form cerebral organoids developing amyloid and Tau pathology. BMI1 overexpression in AD neurons mitigates amyloid and tau accumulation, heterochromatin fragmentation, and G4 DNA induction. These findings implicate reprogramming resistant epigenomic anomalies or uncharacterized genetic alterations working in trans on the epigenome in AD pathophysiology.
- organism: human
- assay: ATAC-seq
- assay: DNA methylation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: statistical model
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Epigenome erosion in Alzheimer's disease brain cells and induced neurons
Bang-An Wang, Jeffrey R. Jones, … Joseph R. Ecker·bioRxiv·Oct 15, 2023
- Proteomic analysis across patient iPSC-based models and human post-mortem hippocampal tissue reveals early cellular dysfunction, progression, and prion-like spread of Alzheimer s disease pathogenesis
Yuriy Pomeshchik, Erika Velásquez, … Laurent Roybon·Acta Neuropathologica CommunicationsPeer-reviewed·Sep 15, 2023
- Excitatory neurons derived from human induced Pluripotent Stem Cells show transcriptomic differences in Alzheimers patients from controls
Ram Sagar, Ioannis Azoidis, … Dimitrios Avramopoulos·CellsPeer-reviewed·Aug 2, 2023
- Characterization of DNA methylation in PBMCs and donor-matched iPSCs shows methylation is reset during stem cell reprogramming
Xylena Reed, Cory A. Weller, … Mark Cookson·bioRxiv·Dec 13, 2024
- Impaired ZNF560 repression during induced pluripotent stem cell reprogramming indicates early epigenetic alterations in Schizophrenia
Bárbara S. Casas, Elvis Acevedo, … Martin A. Montecino·bioRxiv·Aug 21, 2026
- 3D bioengineered neural tissue generated from patient-derived iPSCs develops time-dependent phenotypes and transcriptional features of Alzheimer's disease
Selene Lomoio, Ravi S. Pandey, … Giuseppina Tesco·Molecular PsychiatryPeer-reviewed·Jun 26, 2023